On the public citation graph
Expanded use of sodium‐glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction
0 signed · 68 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamacardio.2021.1437openalex-snapshot
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
inferredcites →https://doi.org/10.1001/jamacardio.2022.4348openalex-snapshot
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
inferredcites →https://doi.org/10.1001/jamacardio.2023.0077openalex-snapshot
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
inferredcites →https://doi.org/10.1001/jamanetworkopen.2021.14501openalex-snapshot
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
inferredcites →https://doi.org/10.1002/ehf2.14309openalex-snapshot
Differences in Red Blood Cell Mass Profiles Impact Intravascular Volume and Outcome Risk in Chronic Heart Failure
inferredcites →https://doi.org/10.1002/ejhf.1713openalex-snapshot
Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
inferredcites →https://doi.org/10.1002/ejhf.2086openalex-snapshot
Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic
inferredcites →https://doi.org/10.1002/ejhf.2249openalex-snapshot
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
inferredcites →https://doi.org/10.1002/ejhf.2558openalex-snapshot
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER ‐like endpoint definitions
inferredcites →https://doi.org/10.1007/s00125-018-4670-7openalex-snapshot
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
inferredcites →https://doi.org/10.1007/s40273-020-00952-0openalex-snapshot
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)
inferredcites →https://doi.org/10.1016/j.ahj.2020.10.071openalex-snapshot
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
inferredcites →https://doi.org/10.1016/j.cardfail.2023.02.011openalex-snapshot
Multidisciplinary Care in Heart Failure Services
inferredcites →https://doi.org/10.1016/j.jacc.2017.06.016openalex-snapshot
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
inferredcites →https://doi.org/10.1016/j.jacc.2021.01.044openalex-snapshot
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
inferredcites →https://doi.org/10.1016/j.jacc.2021.12.011openalex-snapshot
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
inferredcites →https://doi.org/10.1016/j.jacc.2023.01.049openalex-snapshot
Heart Failure With Preserved Ejection Fraction
inferredcites →https://doi.org/10.1016/j.jacc.2023.03.393openalex-snapshot
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction
inferredcites →https://doi.org/10.1016/j.jchf.2020.11.009openalex-snapshot
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
inferredcites →https://doi.org/10.1016/j.jchf.2021.05.006openalex-snapshot
Empagliflozin-Induced Changes in Epicardial Fat
inferredcites →https://doi.org/10.1016/j.jchf.2021.05.019openalex-snapshot
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
inferredcites →https://doi.org/10.1016/s0140-6736(03)14285-7openalex-snapshot
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
inferredcites →https://doi.org/10.1016/s0140-6736(10)61198-1openalex-snapshot
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
inferredcites →https://doi.org/10.1016/s0735-1097(02)01903-4openalex-snapshot
The regulation and measurement of plasma volume in heart failure
inferredcites →https://doi.org/10.1038/969openalex-snapshot
Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger
inferredcites →https://doi.org/10.1038/s41591-021-01536-xopenalex-snapshot
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
inferredcites →https://doi.org/10.1038/s41591-021-01659-1openalex-snapshot
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
inferredcites →https://doi.org/10.1056/nejmoa1313731openalex-snapshot
Spironolactone for Heart Failure with Preserved Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa1409077openalex-snapshot
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1812389openalex-snapshot
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1812851openalex-snapshot
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa1908655openalex-snapshot
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa1911303openalex-snapshot
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa1915928openalex-snapshot
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa2022190openalex-snapshot
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa2030183openalex-snapshot
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa2107038openalex-snapshot
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
inferredcites →https://doi.org/10.1093/ehjci/jew131openalex-snapshot
Global myocardial oedema in advanced decompensated heart failure
inferredcites →https://doi.org/10.1093/ehjcvp/pvab056openalex-snapshot
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence
inferredcites →https://doi.org/10.1093/eurheartj/ehab497openalex-snapshot
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
inferredcites →https://doi.org/10.1111/dom.12127openalex-snapshot
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.13126openalex-snapshot
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
inferredcites →https://doi.org/10.1161/cir.0000000000000042openalex-snapshot
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
inferredcites →https://doi.org/10.1161/cir.0000000000001052openalex-snapshot
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
inferredcites →https://doi.org/10.1161/circheartfailure.115.002922openalex-snapshot
Fluid Volume Overload and Congestion in Heart Failure
inferredcites →https://doi.org/10.1161/circheartfailure.120.007197openalex-snapshot
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors
inferredcites →https://doi.org/10.1161/circresaha.116.310119openalex-snapshot
Why Don’t We Have Proven Treatments for HFpEF?
inferredcites →https://doi.org/10.1161/circresaha.121.318186openalex-snapshot
Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
inferredcites →https://doi.org/10.1161/circulationaha.114.013255openalex-snapshot
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
inferredcites →https://doi.org/10.1161/circulationaha.117.028268openalex-snapshot
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
inferredcites →https://doi.org/10.1161/circulationaha.118.037778openalex-snapshot
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
inferredcites →https://doi.org/10.1161/circulationaha.119.045561openalex-snapshot
Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance
inferredcites →https://doi.org/10.1161/circulationaha.120.048739openalex-snapshot
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure
inferredcites →https://doi.org/10.1161/circulationaha.120.052503openalex-snapshot
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure
inferredcites →https://doi.org/10.1161/circulationaha.122.059038openalex-snapshot
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
inferredcites →https://doi.org/10.1161/circulationaha.122.061732openalex-snapshot
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
inferredcites →https://doi.org/10.1186/s12933-020-01175-5openalex-snapshot
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
inferredcites →https://doi.org/10.1253/circrep.cr-21-0134openalex-snapshot
Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society
inferredcites →https://doi.org/10.15420/cfr.2022.08openalex-snapshot
In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
inferredcites →https://doi.org/10.15420/cfr.2022.11openalex-snapshot
Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
inferredcites →https://doi.org/10.2337/dc19-2187openalex-snapshot
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
inferredcites →https://doi.org/10.2337/dci19-0074openalex-snapshot
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
inferredcites →https://doi.org/10.3390/healthcare10112133openalex-snapshot
Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure
inferredcites →https://doi.org/10.3390/ijms22157976openalex-snapshot
Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
inferredcites →https://doi.org/10.3390/ijms23158631openalex-snapshot
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4822553openalex-extracted
A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024
inferred← citeshttps://doi.org/10.1002/phar.70140openalex-snapshot
Exploring the Rabbit Holes of Pharmacotherapy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.